PubMed Health⌕ Search

PubMed · 3777361

Smoke inhalation injuries.

Abstract

Up to a third of all victims of major burns suffer smoke-related injury and may die as a result of inhalation injury. The management of the upper airway depends on a thorough understanding of the mechanisms of injury, including carbon monoxide toxicity, thermal injury, and smoke inhalation. Establishing and maintaining an airway for resuscitation requires a high index of suspicion, as early and severe upper airway swelling may preclude safe intubation under direct vision. Nasotracheal intubation is preferred in burn patients but is only indicated for patients in acute respiratory distress and a select group at high risk for developing progressive upper airway compromise and pulmonary injury. The use of the flexible bronchoscope and nasopharyngoscope is a safe and effective means of evaluating the respiratory tract and assisting in pulmonary therapy. Early tracheotomy is indicated only in rare cases because of increased morbidity and mortality in burn patients. The use of steroids is still controversial and is probably indicated only for refractory bronchospasm or secretions. Aggressive evaluation and management of inhalation burns will reduce the mortality rate of a frequently fatal injury.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Robinson, R H Miller. Smoke inhalation injuries.. https://doi.org/10.1016/s0196-0709(86)80028-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗